Enhabit, Inc.: A Sell Rating Amid Overly Optimistic Growth Expectations and Financial Challenges
Enhabit Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD) and Enhabit, Inc (EHAB)
UBS Adjusts Enhabit Price Target to $10 From $9.50, Maintains Neutral Rating
Enhabit, Inc (EHAB) Receives a Rating Update From a Top Analyst
Analysts Have Conflicting Sentiments on These Healthcare Companies: Enhabit, Inc (EHAB) and UnitedHealth (UNH)
Enhabit Analyst Ratings
Enhabit Analyst Ratings
Jefferies Maintains Buy on Enhabit, Lowers Price Target to $14
TD Cowen Remains a Hold on Enhabit, Inc (EHAB)
TD Cowen Initiates Coverage On Enhabit With Market Perform Rating, Announces Price Target of $12
Enhabit Analyst Ratings
Analysts Conflicted on These NA Names: Enhabit, Inc (EHAB) and Forestar Group (FOR)
Weak Performance and High Leverage: Maintaining Sell Rating for Enhabit, Inc
Analysts Conflicted on These NA Names: Enhabit, Inc (EHAB) and Fortrea Holdings Inc. (FTRE)
Goldman Sachs Sticks to Its Hold Rating for Enhabit, Inc (EHAB)
Credit Suisse Maintains Neutral on Enhabit, Lowers Price Target to $12
Enhabit Analyst Ratings
Bank of America Securities Remains a Sell on Enhabit, Inc (EHAB)
Enhabit, Inc (EHAB) Gets a Hold From Credit Suisse
No Data